Impact of intranasal corticosteroid on endothelial function of children with primary snoring

A randomized study of intranasal corticosteroid for childhood primary snoring – endothelial function perspective

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14004138

Enrollment

Unknown

Registered

2014-01-15

Start date

2014-04-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary snoring

Interventions

Two groups:budesonide 32mcg one spray per nostril once daily vs no treatment (watchful waiting as controls), for four months

Eligibility

Sex/Gender

Male

Age

8 Years to 16 Years

Inclusion criteria

Inclusion criteria: (i) Hong Kong Chinese children and adolescents aged between 8-16 years; (ii) Normal sleep study as documented on PSG (OAHI <1); (iii) Non-smoker; (iv) Written informed consent obtained from parents.

Exclusion criteria

Exclusion criteria: (i) Obesity, defined as having a body mass index (BMI) =95th percentile (corresponding to a z score of 1.645) of the local reference; (ii) Known medical conditions that could affect airway, BP control and endothelial function, for example cranio-facial, neuromuscular diseases and congenital heart disease; (iii) Receiving medications that could alter BP control and endothelial function; (iv) Upper respiratory tract or other infection within the past 4 weeks from recruitment.

Design outcomes

Primary

Measure	Time frame
flow-mediated dilatation of brachial arter;	—

Countries

China

Contacts

Public ContactAlbert Martin Li

albertmli@cuhk.edu.hk+852 26322917

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026